Hospira Quality Problems Lead to Recall, Creates Ripple Effect

Drug GMP Report
Quality issues and violations of FDA current good manufacturing practices are plaguing Hospira, triggering a series of recalls, contributing to a drug shortage and costing the drugmaker’s parent company a biosimilar license for a second time.

To View This Article:


Subscribe To Drug GMP Report